Genalyte has released its rapid SARS-CoV-2 Multi-Antigen Serology Panel, a COVID-19 diagnostic that can detect antibodies in patients who have had the virus.
The diagnostic is run on Genalyte’s Maverick platform. The panel tests for the detection of IgG and IgM antibodies that the body produces in response to SARS-CoV-2. Utilizing a machine learning approach, the panel is able to eliminate false positives, achieving 100% specificity on a cohort of 300 negative patients, according to the company.